Last reviewed · How we verify
Valsartan plus HCTZ
At a glance
| Generic name | Valsartan plus HCTZ |
|---|---|
| Sponsor | Novartis |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control (NA)
- Integration of Hypertension Management in HIV Care in Uganda (NA)
- Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (PHASE3)
- BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333) (PHASE3)
- Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension (PHASE3)
- VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil (PHASE3)
- Hypertension and Cardiovascular Risk Factors (PHASE4)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |